Back to Search
Start Over
A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
- Source :
-
American journal of hematology [Am J Hematol] 2019 Dec; Vol. 94 (12), pp. E319-E322. Date of Electronic Publication: 2019 Oct 04. - Publication Year :
- 2019
- Subjects :
- Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols adverse effects
Dexamethasone administration & dosage
Dexamethasone adverse effects
Drug Resistance, Neoplasm
Female
Humans
Lenalidomide administration & dosage
Lenalidomide adverse effects
Male
Maximum Tolerated Dose
Middle Aged
Progression-Free Survival
Recurrence
Thalidomide administration & dosage
Thalidomide adverse effects
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Multiple Myeloma drug therapy
Salvage Therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1096-8652
- Volume :
- 94
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- American journal of hematology
- Publication Type :
- Report
- Accession number :
- 31489991
- Full Text :
- https://doi.org/10.1002/ajh.25633